GlassScriptPhysician profile
Christine Zerr
NPI 1417482282
$68,136.44
in general payments reported to CMS, 2019-2025
34 companies · $28K in 2025
The $28K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,438 · 2022: $3,548 · 2023: $9,602 · 2024: $25K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Food and Beverage: $16K · Consulting Fee: $6,506 · Travel and Lodging: $4,216 · Education: $472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,983.50 |
| Food and Beverage | $15,973.09 |
| Consulting Fee | $6,506.00 |
| Travel and Lodging | $4,216.11 |
| Education | $471.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $31,503.58 | 2021-2025 | |
| Genzyme Corporation | $13,847.07 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $5,763.40 | 2023-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $2,533.25 | 2023-2025 | Zoryve |
| Pfizer INC. | $2,129.58 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,601.17 | 2021-2025 | |
| Galderma Laboratories, L.P. | $1,276.52 | 2021-2025 | Nemluvio, Dysport, Aklief |
| Sun Pharmaceutical Industries INC. | $1,253.52 | 2021-2025 | Winlevi, Ilumya, Blu-U |
| Regeneron Healthcare Solutions, INC. | $1,051.50 | 2021-2025 | Dupixent, Libtayo |
| Amgen INC. | $983.92 | 2022-2025 | Otezla, Otezla, Enbrel |
| Ucb, INC. | $916.81 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $914.71 | 2021-2025 | Tremfya, Simponi, Stelara |
| Incyte Corporation | $866.56 | 2021-2025 | Opzelura, Opzelura |
| Leo Pharma INC. | $702.48 | 2021-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $502.05 | 2021-2025 | Olumiant, Taltz, Ebglyss |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $481.05 | 2021-2025 | Jublia, Cabtreo |
| Almirall LLC | $270.49 | 2021-2022 | |
| Dermavant Sciences, INC. | $254.19 | 2023-2024 | Vtama |
| Organon LLC | $252.61 | 2024-2025 | Vtama |
| Epi Health, LLC | $243.91 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $211.97 | 2021 | |
| Paratek Pharmaceuticals, INC. | $197.84 | 2022-2025 | Nuzyra |
| Journey Medical Corporation | $91.52 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $75.97 | 2024-2025 | Tremfya |
| Convatec INC. | $37.73 | 2025 | |
| Verrica Pharmaceuticals INC. | $26.98 | 2023 | Ycanth |
| Organogenesis INC. | $25.83 | 2025 | Apligraf |
| Dermira, INC. | $22.76 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.13 | 2023 | Spevigo |
| Genentech USA, INC. | $17.91 | 2024 | Erivedge |
| Teva Pharmaceuticals USA, INC. | $15.99 | 2024 | Simlandi |
| Blueprint Medicines Corporation | $14.71 | 2024 | Ayvakit |
| Allergan, INC. | $14.30 | 2021 | |
| Exeltis, USA INC. | $13.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Zerr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.